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It has been estimated by the World Health Organi­
zation (WHO) that a third of the world’s population 
is infected with Mycobacterium tuberculosis (MTB), 
with a tuberculosis (TB) incidence of 981/100  000 
in South Africa.[1] Of TB infections, 16% involve 
extra­pulmonary systems and 1% affect the spine. Alarmingly, of all 
patients treated for spinal TB, only 55% have a definitive laboratory 
diagnosis, with 19% being negative and 26% having no traceable 
results.[2] Although effective chemotherapy has been available for 
over 50 years, TB remains one of the most challenging diseases to 
manage. Timely diagnosis and adequate treatment of spinal TB are 
necessary to prevent serious morbidity, including spinal deformity 
and, ultimately, neurological sequelae. Spinal cord compression from 
pus, inflammatory granulation tissue of active disease, or kyphosis 
deformity in the late stage of disease can result in paraplegia.[3] As the 
majority of cases are managed medically, a reliable confirmation of 
spinal TB diagnosis is crucial. 
Methods
We performed a retrospective, multicentre review of 44 consecutive 
patients who presented at Tygerberg Hospital (TBH) or Groote 
Schuur Hospital (GSH) between January 2009 and April 2012 
and had clinical and radiological evidence of spinal TB. All had 
undergone percutaneous transpedicular needle biopsy to confirm 
diagnosis and were identified from surgical databases kept by their 
respective surgeons. All patients had strong clinical and radiological 
evidence of TB and had magnetic resonance imaging (MRI) scans as 
part of their workup. Exclusion criteria included absolute indications 
for further surgical management and questionable diagnoses where 
biopsy was undertaken to rule out non­infectious processes. 
Patients waited an average of 11.9 days prior to biopsy, allowing 
for full workup. There were 20 males and 24 females, ranging in 
age from 16 to 89 years (mean 39 years). All had a history of lower 
back pain, with an average 6­month duration of symptoms prior to 
presentation. On examination, 24 (54%) had a neurological deficit 
ranging from sensory fallout to myelopathy with muscle weakness. 
Nearly half had constitutional symptoms of TB, including weight loss, 
night sweats, loss of appetite and general malaise. Fourteen patients 
were HIV­positive, 21 HIV­negative and the rest refused testing. 
Seven of the HIV­positive patients were established on antiretroviral 
treatment (ART), and none had any other AIDS­defining disease. Six 
patients had a history of previous TB, of whom 4 were HIV­positive. 
As all subjects were referred from secondary level institutions, 7 had 
already been started on the 4­drug TB treatment regimen, with a 
varying duration of treatment at presentation (5 ­ 70 days).
Included in the initial blood workup was the erythrocyte 
sedimentation rate (ESR), a nonspecific inflammatory marker often 
elevated in TB, measured using the Westergren method. The ESR 
ranged from 3 to 150 mm/hour (mean 72 mm/hour). All patients 
had plain X­rays of the chest and spine in the initial radiological 
workup. Spinal radiology revealed typical features ranging from 
osteopenia, paravertebral abscess and disc space reduction to end 
plate erosions and vertebral body collapse. On MRI, 21 patients had 
abscess formation, which was epidural in 8 and pre­vertebral in 13. 
One patient had arachnoiditis. Five patients had disease involving 
more than 2 vertebrae.
At the time of biopsy, patients were given a general anaesthetic and 
either positioned prone or on their right side. A Jamshidi or Harlow 
Wood needle was advanced percutaneously under fluoroscopic 
guidance into the affected vertebral body, utilising the transpedicular 
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approach. Almost all patients had either a thoracic or lumbar biopsy. 
In 2 patients, cervical spine biopsy was achieved via a trans­oral 
approach for atlanto­axial pathology. A pus sample and 2 trephine 
biopsies of bone (average length 7.92 mm) were collected from 
each patient. All samples underwent histopathological examination, 
microscopy and culture, and polymerase chain reaction (PCR) 
analysis for MTB DNA. 
Results
The gold standard for the definitive diagnosis of TB remains the 
identification of MTB; therefore, all results were measured against 
a positive or negative culture.[4] To identify factors influencing the 
overall culture yield of biopsies, the study population was split into 
2 groups: culture­positive and culture­negative. Of the 44 patients, 
26 (59%) had biopsies that cultured positive for TB. Age, duration 
of symptoms, HIV status and neurological status had no statistical 
influence on this outcome of culture positivity.
There was no statistical significance when comparing the average 
ESR values of the culture­positive and ­negative groups (mean 69.7, 
standard deviation (SD) ±37.5 v. 74.8±37.6, respectively). However, 
there was a definite downward trend in ESR from commencement to 
completion of treatment in both groups (Fig. 1), with patients being 
treated for an average of 12.4 months (mean 12; SD ±4; range 12 ­ 24). 
The classic histological finding is one of necrotising granulomas 
with epithelioid macrophages, multiple giant cells and lymphocytes. 
Because this picture can change in HIV­positive individuals, non­
necrotising granulomatous inflammatory changes may also be found 
in TB culture­positive specimens.[4] Fig. 2 shows the comparison 
between the histology and the culture results of the same specimen. 
Unexpectedly, the highest culture yield came from samples showing 
non­necrotising chronic inflammatory changes (32%), followed by 
samples with nonspecific histological findings (27%) and not from 
samples showing necrotising granulomas. Samples showing classic 
TB histology were associated with a positive culture in only 23% of 
cases. Only 2 specimens stained positive for acid­fast bacilli and of 
the 59% of positive cultures, 12% were multidrug resistant (MDR). 
All drug sensitivities were confirmed with PCR.
Biopsy core length had no significant impact on culture yield. The 
negative group, in fact, had the largest average core size (mean 9 mm 
v. 7 mm) (Fig. 3). A possible explanation is that these larger core sizes 
were due to removing the trocar too soon, thereby sampling a greater 
proportion of healthy pedicular bone. 
The potential effect of active TB treatment on culture yield was 
of concern. Seven patients were receiving TB therapy by the time 
of spinal biopsy, 3 of which were culture­positive. Although a trend 
towards positive culture in patients not yet started on TB treatment 
could be identified, this was not statistically significant (p=0.0518, 
Fisher’s exact two­tailed test).
There was a similar histological yield of the biopsies between the 
individual hospitals (56%). Of the 44 samples, 10 were diagnostic 
and 13 were suggestive of TB infection (but showing non­
necrotising granulomatous inflammation). There was, however, a 
significant difference in the yield from culture despite the biopsies 
being performed by the same surgeons at both hospitals: positive 
results at TBH only reached 40% compared with 75% at GSH. On 
examining the standard operating procedure (SOP) at the TBH 
National Health Laboratory Service (NHLS) laboratory, it was 
found that all samples were routinely decontaminated before being 
prepared for culture, leading to loss of viable bacilli and a lower 
culture yield. The SOP at GSH NHLS laboratory differed in that 
core specimens were treated as sterile and only decontaminated 
when they were flagged as growing other bacteria. This was brought 
to the attention of the relevant microbiologists, who have since 
changed their practice. 
Discussion
There is no single test that can be performed for the detection of 
all musculoskeletal cases of TB. The diagnosis of spinal disease 
remains a challenge. The treating physician must have a high 
index of suspicion and has to rely on observation and thorough 
investigation of clinical signs and symptoms, augmented by the use of 
various imaging techniques and laboratory methods.[4] Patients may 
complain of back pain, night sweats, loss of weight and appetite. They 
may also have neurological symptoms ranging from clumsiness, with 
Fig. 1. Radiographic appearance of tuberculosis of the spine. (A) Plain 
roëntgen and (B) magnetic resonance imaging.
Fig. 2. Fluoroscopic-guided transoral needle biopsy.
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subtle myelopathic signs, to complete motor fallout. In active TB, a 
low haemoglobin level, relative lymphocytosis and a raised ESR may 
be found.[5,6] Because these are all nonspecific findings, results serve 
only to support the diagnosis.
Ultimately, identification of the TB bacilli in biopsy specimens 
offers the only definitive diagnosis.[7,8] The gold standard remains 
the culture of MTB, it is much more sensitive than smear 
microscopy and can detect as little as 10 viable MTB bascillus 
per millilitre of sample.[2] In spinal disease, this unfortunately 
requires the invasive procedure of bone biopsy, the diagnosis 
being made histologically when necrotising granulomatous 
inflammation showing epithelioid macrophages, multiple giant 
cells and lymphocytes are demonstrated. In patients with HIV, and 
more specifically AIDS, the histological changes caused by MTB 
can range from the classic caseating granulomas, to a nonspecific 
chronic inflammatory reaction without necrosis.[4] Ziehl­Neelsen 
staining is then key to the identification of the presence of acid­
fast bacilli. Regrettably, because of the typically low bacterial loads 
in TB of the spine, bacteria are only identifiable in ≤50% of cases 
using minimally invasive techniques.[9] Moreover, confirming the 
diagnosis histologically is but half the battle, as sensitivity to first­
line drugs still has to be proven. 
In endemic areas, the diagnosis of spinal TB is often made on 
clinical suspicion, radiographic evidence and blood­test results 
alone, and treatment is started empirically.[5,10] Danchaivijitr et al.[3] 
identified patients with spinal TB based on either histopathological, 
microbiological or typical radiological findings and showed good 
response to anti­TB treatment in all 3 groups. At a time when drug 
resistance is growing at an alarming rate, and with TB being the 
great mimicker, it is important to have a histopathological diagnosis 
together with a drug sensitivity profile to achieve a definitive 
diagnosis and treatment.[10­12] MDR­TB is estimated to account for 
1.8% of new TB cases and 6.7% of re­treatment cases.[1] The current 
guidelines for the management of spinal TB include percutaneous 
vertebral needle biopsy as a diagnostic tool before treatment is 
started[10] to confirm MTB as the responsible pathogen and its 
sensitivity to first­line treatment. A recent meta­analysis that focused 
on core needle biopsy to achieve TB diagnosis revealed an overall TB 
culture yield of 66% (range 50 ­ 83) in 299 biopsies.[13]
A retrospective study in 2005 focused on 70 adult patients 
with clinico­radiological proof of thoracic spinal TB. Computed 
tomography (CT)­guided needle biopsies were performed in 11 cases 
– 3 yielded positive cultures for TB and 5 showed evidence of TB on 
histology. All 3 culture specimens showed resistance to first­line drugs. 
Another 10 of the 70 patients in this study failed to respond to first­
line TB treatment and were diagnosed with MDR­TB by default and 
subsequently successfully treated.[6] Although systematic follow­up 
and continuous monitoring can ensure that such resistant cases are 
ultimately detected, not testing for drug susceptibility risks a delay of 
between 7 and 8 months before institution of appropriate therapy.[11] 
It is important to scrutinise biopsy results and to be aware 
of the techniques used in the processing of samples by the 
respective microbiology laboratory. In this study, there was clearly 
an inconsistency in the results obtained from the respective 
laboratories, with the difference identified in the TBH NHLS SOP 
of decontaminating biopsy samples prior to culturing for TB. This 
procedure is meant to selectively eliminate bacteria other than 
mycobacteria and makes use of sodium hydroxide­N­acetyl­L­
cysteine to liquify samples. A phosphate buffer is then added to 
the mixture, which is then concentrated by centrifugation. The 
supernatant is decanted, leaving the sediment to be cultured. Prior 
to inoculation into the MTB growth indicator tube (MGIT), an 
antibiotic mixture, referred to as PANTA, is added to the culture 
broth.[14] PANTA comprises 5 antimicrobial agents: polymyxin B, 
amphotericin B, nalidixic acid, trimethoprim and azlocillin. The 
addition of this antibiotic mixture has been found to increase rather 
than decrease MTB culture yields.[15] 
Thus, the most obvious explanation for the loss of viable bacilli 
would have to be the dilution and increased decanting of the specimen 
by the addition of PANTA. Extra N­acetyl­L­cysteine powder would 
have had to be added to adequately liquefy the core biopsy sample, 
which in turn meant more phosphate buffer and consequently more 
supernatant requiring decanting. Both laboratories now practise 
direct inoculation into a MGIT tube without adding any PANTA, 
and decontamination is only performed if the specimen appears to 
be growing bacteria other than mycobacteria.
Compared with published data, the overall yield from needle 
biopsies performed in this study is commensurate with international 
experience. The factors that could be identified as having directly 
influenced biopsy yield were two­fold, i.e. that the patient was 
receiving TB treatment at time of biopsy and the routine practice of 
decontaminating specimens prior to culture. The results of this study 
Fig. 1. Erythrocyte sedimentation rate (ESR) through the course of treatment (Rx).
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Fig. 2. Comparison between histology results and culture of the same specimen.
Fig. 3. Specimen core size with respect to culture result. 
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suggest that every patient with a clinical and radiological suspicion 
of spinal TB should undergo core needle biopsy in the diagnostic 
workup. Where TB treatment has already been initiated, the surgeon 
should recognise the probability of a negative MTB culture. Such 
patients may be treated empirically and only be biopsied when there 
is suspicion of drug resistance or non­infective pathology. 
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